07:28 AM EDT, 08/11/2025 (MT Newswires) -- Apogee Therapeutics ( APGE ) reported Monday a Q2 net loss after tax of $66.1 million, widening from a loss of $33.8 million a year earlier.

Analysts polled by FactSet expected a loss of $62.8 million.

The company reported no revenue for the quarter ended June 30.

Apogee said its cash, cash equivalents, and marketable securities of $621.2 million as of June 30 would be enough to fund operations into Q1 2028.

Shares of the clinical stage biotechnology company were down 1% in recent premarket activity Monday.